BIO-key Files S-1 for 6.18M Share Resale, Eyes $6.3M from Warrant Exercise

TL;DR

**BKYI's S-1 for 6.18M share resale is a major dilution risk, but warrant exercise could bring in $6.3M, a necessary cash injection for this small-cap IAM player.**

AI Summary

BIO-key International, Inc. (BKYI) filed an S-1 to register the resale of up to 6,183,336 shares of common stock by a selling stockholder, issuable upon the exercise of warrants. The company will not receive any proceeds from the sale of these shares by the selling stockholder. However, if the selling stockholder exercises all warrants, BIO-key expects to receive aggregate gross proceeds of $6,307,002.72, which will be used for working capital and general corporate purposes, including repayment of a portion of its outstanding secured note. As of November 13, 2025, BIO-key had 10,836,618 shares of common stock outstanding. The 6,183,336 shares offered represent approximately 36% of the common stock outstanding after the assumed full exercise of the warrants, potentially diluting existing shareholders. The company operates a SaaS business model in identity access management (IAM) and acquired Swivel Secure in 2022 to expand its EMEA presence. BIO-key's strategic outlook includes expanding its IAM market role, growing in government, higher education, and highly-regulated industries, and pursuing strategic acquisitions in the IAM space.

Why It Matters

This S-1 filing signals potential significant dilution for existing BIO-key investors, as the 6,183,336 shares represent about 36% of the post-warrant exercise outstanding common stock. While the company won't directly benefit from the resale, the exercise of warrants could inject over $6.3 million into BIO-key for working capital and debt repayment, which is crucial for its growth strategy in the competitive IAM market against larger players. The increased float could also impact stock price volatility, affecting both current shareholders and new investors. For employees and customers, the capital infusion could support continued product development and market expansion, particularly in government and healthcare sectors.

Risk Assessment

Risk Level: high — The filing explicitly states that the 6,183,336 shares offered for resale represent approximately 36% of the outstanding common stock following the assumed full exercise of the warrants. This substantial increase in tradable shares could lead to significant downward pressure on the stock price, impairing the company's ability to raise future funds. The 'Risk Factors' section also warns that 'Sales of a substantial number of shares of our common stock in the public market... could lower our stock price and impair our ability to raise funds in new stock offerings.'

Analyst Insight

Investors should carefully evaluate the potential for significant dilution and increased selling pressure on BKYI's stock price due to the 36% increase in outstanding shares. While the $6.3 million from warrant exercises offers a cash infusion, the immediate impact on market valuation could be negative. Consider holding off on new positions until the market absorbs this increased supply, or if already invested, assess your risk tolerance for potential short-term price declines.

Key Numbers

• 6,183,336 — Shares of Common Stock Offered (Represents approximately 36% of outstanding common stock post-warrant exercise, indicating significant potential dilution.)
• $6.31M — Expected Proceeds from Warrant Exercise (Funds for working capital and debt repayment, crucial for company operations and strategic initiatives.)
• $1.03 — Closing Stock Price (As of November 18, 2025, providing a baseline for potential market impact.)
• 10,836,618 — Common Stock Outstanding (As of November 13, 2025, before the potential exercise of warrants.)
• 36% — Dilution Percentage (Approximate percentage of outstanding common stock represented by the shares offered, assuming full warrant exercise.)
• 17 — Strong Authentication Factors (Number of authentication factors leveraged by BIO-key's biometric core platform.)
• 21.7M — Bank Customers Identified (Number of customers a large bank identifies using BIO-key fingerprint biometrics daily.)
• 85 — Channel Alliance Program Participants (Number of participants in BIO-key's growing channel alliance program.)
• 2022 — Acquisition Year (Year BIO-key acquired Swivel Secure, expanding its product offerings and customer base.)
• 1 — Weighted Average Contract Duration (In years, for noncancelable subscription contracts, indicating recurring revenue stability.)

Key Players & Entities

• BIO-key International, Inc. (company) — Registrant and IAM platform provider
• Nasdaq Capital Market (regulator) — Stock exchange where BKYI is listed
• Michael DePasquale (person) — Chief Executive Officer of BIO-key International, Inc.
• Vincent A. Vietti (person) — Esquire at Fox Rothschild LLP, counsel for BIO-key
• Swivel Secure (company) — Acquired IAM solutions provider, now BIO-key EMEA
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• $1.03 (dollar_amount) — Closing price of BKYI common stock on November 18, 2025
• $6,307,002.72 (dollar_amount) — Aggregate gross proceeds BIO-key expects from warrant exercises
• 6,183,336 (dollar_amount) — Number of shares of common stock offered by selling stockholder
• 10,836,618 (dollar_amount) — Shares of common stock outstanding as of November 13, 2025

FAQ

Risk Factors

• Dilution from Resale of Shares [high — market]: The resale of 6,183,336 shares, representing approximately 36% of outstanding common stock post-warrant exercise, could significantly lower the stock price and impair the company's ability to raise future capital. This is compounded by potential sales from other warrant holders and Rule 144 resales.
• Lack of Sustained Active Trading Market [medium — market]: Despite being listed on the Nasdaq Capital Market, the trading activity for BIO-key's shares has been variable. An inactive or illiquid market could negatively impact the stock price and investor confidence.
• Dependence on Warrant Exercise for Capital [medium — financial]: The company expects to receive up to $6.31 million from the exercise of warrants, which will be used for working capital and debt repayment. This reliance on warrant exercise highlights potential cash flow constraints if not fully realized.
• Integration of Swivel Secure [medium — operational]: The acquisition of Swivel Secure in 2022 was intended to expand EMEA presence. The success of this integration and its contribution to the company's strategic goals are critical for future growth.
• Competition in Identity Access Management (IAM) [high — market]: BIO-key operates in the competitive IAM market, facing established players and emerging technologies. Expanding market share in government, higher education, and regulated industries requires significant differentiation and execution.

Industry Context

BIO-key operates in the Identity Access Management (IAM) sector, a growing market driven by increasing cybersecurity threats and the need for secure digital access. The company competes with established players and emerging solutions, focusing on biometric authentication and multi-factor authentication. Key growth areas include government, higher education, and highly-regulated industries, where robust security is paramount.

Regulatory Implications

As a publicly traded company, BIO-key is subject to SEC regulations, including timely filings and disclosures. The S-1 filing itself is a regulatory requirement for registering securities for resale. Compliance with data privacy regulations (e.g., GDPR, CCPA) is also critical given the nature of identity management services.

What Investors Should Do

1. Monitor warrant exercise and subsequent share sales: The potential resale of 6,183,336 shares poses significant dilution risk. Investors should track the pace and volume of these sales.
2. Evaluate the company's ability to generate working capital: The expected $6.31 million from warrant exercise is crucial for operations and debt repayment. Assess the company's cash burn and runway.
3. Assess competitive positioning in IAM: Understand how BIO-key differentiates itself and gains market share against larger competitors in its target sectors.
4. Analyze the integration success of Swivel Secure: The acquisition is key to expanding EMEA presence; monitor its financial and operational contributions.
5. Consider the sustainability of the trading market: Given past volatility, assess the liquidity and stability of BIO-key's stock on Nasdaq.

Key Dates

• 2025-04-23: Form 10-K for year ended December 31, 2024 filed — Incorporates by reference risk factors from the previous fiscal year, providing context for current risks.
• 2025-11-13: 10,836,618 shares of common stock outstanding — Establishes the baseline for calculating potential dilution from the current offering.
• 2025-11-18: Closing stock price of $1.03 — Provides a current market valuation reference point for the shares being registered for resale.
• 2023-10-30: Public offering of Units — Resulted in outstanding warrants, the exercise of which is central to the current S-1 filing and potential dilution.
• 2022-01-01: Acquisition of Swivel Secure — Key strategic move to expand EMEA presence and product offerings in the IAM space.

Glossary

S-1 Filing

A registration statement filed with the SEC by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and the securities being offered. (This document is the basis for the current offering and provides essential information for investors.)

Selling Stockholder

An existing holder of a company's securities who is registering their shares for resale to the public. The company does not receive proceeds from these sales. (The current S-1 is primarily for the resale of shares by a selling stockholder, meaning BIO-key will not directly benefit from the share sales.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase shares of a company's stock at a specified price (exercise price) within a certain timeframe. (The shares being registered are issuable upon the exercise of warrants, and their exercise could provide capital to BIO-key.)

Dilution

The reduction in the ownership percentage of existing shareholders when a company issues new shares or when outstanding options/warrants are exercised. (The resale of 6,183,336 shares represents a significant potential dilution of approximately 36% for existing shareholders.)

Identity Access Management (IAM)

A framework of policies and technologies that ensures the right individuals access the right resources at the right times for the right reasons. It is BIO-key's core business area. (BIO-key's strategic focus and growth are centered on expanding its role in this market.)

SaaS

Software as a Service, a software distribution model where a third-party provider hosts applications and makes them available to customers over the Internet. (BIO-key operates under this business model, indicating recurring revenue streams.)

Year-Over-Year Comparison

This S-1 filing focuses on the resale of shares by a selling stockholder, a scenario not typically detailed in a standard annual report. Therefore, a direct comparison of key metrics like revenue growth, margin changes, or new risks to a previous filing is not applicable in the traditional sense. The primary focus here is on the potential dilution and the capital infusion contingent upon warrant exercise, rather than a year-over-year operational performance review.

Key Financial Figures

• $0.0001 — 6 shares of our common stock, par value $0.0001 per share, issuable upon exercise of wa
• $1.03 — e closing price of our common stock was $1.03 per share. We will bear all costs, exp
• $6,307,002 — ill receive aggregate gross proceeds of $6,307,002.72, which we expect to use for working
• $144.71 — th a weighted-average exercise price of $144.71 per share; 11,112 shares of common sto
• $54,00 — th a weighted-average exercise price of $54,00 per share; 421,905 shares of common st
• $3.15 — e of warrants with an exercise price of $3.15 per share; 31,131 shares of common sto
• $0.0018 — nded warrants with an exercise price of $0.0018 per share; 732,548 shares of common st

Filing Documents

• bkyi20251120_s1.htm (S-1) — 297KB
• ex_891062.htm (EX-5.1) — 9KB
• ex_891964.htm (EX-23.1) — 4KB
• ex_891063.htm (EX-FILING FEES) — 25KB
• bushcpa.jpg (GRAPHIC) — 8KB
• footer.jpg (GRAPHIC) — 17KB
• foxlogo2.jpg (GRAPHIC) — 9KB
• foxlogo.jpg (GRAPHIC) — 18KB
• logo.jpg (GRAPHIC) — 11KB
• 0001437749-25-036032.txt ( ) — 727KB
• bkyi-20251231.xsd (EX-101.SCH) — 5KB
• bkyi-20251231_def.xml (EX-101.DEF) — 11KB
• bkyi-20251231_lab.xml (EX-101.LAB) — 25KB
• bkyi-20251231_pre.xml (EX-101.PRE) — 12KB
• bkyi20251120_s1_htm.xml (XML) — 3KB
• ex_891063_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 5 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 6 THE OFFERING 6

USE OF PROCEEDS

USE OF PROCEEDS 7 DETERMINATION OF OFFERING PRICE 7 SELLING STOCKHOLDER 8 PLAN OF DISTRIBUTION 9

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 10 LEGAL MATTERS 12 EXPERTS 13 WHERE YOU CAN FIND MORE INFORMATION 13 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 13 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 14 ABOUT THIS PROSPECTUS We have not authorized anyone to provide you with information that is different from that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither the delivery of this prospectus nor the sale of our securities means that the information contained in this prospectus or any free writing prospectus is correct after the date of this prospectus or such free writing prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer or solicitation is unlawful. The information in this prospectus is accurate only as of the date on the front cover of this prospectus and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of that free writing prospectus. Our business, financial condition, results of operations and prospects may have changed since those dates. No person is authorized in connection with this prospectus to give any information or to make any representations about us, the securities offered hereby or any matter discussed in this prospectus, other than the information and representations contained in this prospectus. If any other information or representation is given or made, such information or representation may not be relied upon as having been authorized by us. For investors outside the United States: We have not taken any action that would permit this offering or possession or distribution of this prospectus in any jurisdi

RISK FACTORS

RISK FACTORS Investing in our securities involves a high degree of risk. Before deciding to invest in our securities, you should consider carefully the risks and uncertainties described below and under Item 1A. " Risk Factors " in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission, or SEC, on April 23, 2025, which are incorporated by reference in this prospectus, together with all of the other information contained in this prospectus and documents incorporated by reference herein, and in any free writing prospectus that we have authorized for use in connection with this offering. If any of the matters discussed in the following risk factors were to occur, our business, financial condition, results of operations, cash flows or prospects could be materially adversely affected, the market price of our common stock could decline and you could lose all or part of your investment in our securities. Additional risks and uncertainties not presently known or which we consider immaterial as of the date hereof may also have an adverse effect on our business. RISKS RELATED TO THIS OFFERING Sales of a substantial number of shares of our common stock in the public market, including the shares offered under this prospectus, could lower our stock price and impair our ability to raise funds in new stock offerings. If our stockholders sell substantial amounts of our common stock, the market price of our common stock could decrease. We had 10,836,618 shares of common stock outstanding as of November 13, 2025. Under this registration statement, we are registering the resale of 6,183,336 shares of common stock held by the selling stockholder, all of which are issuable upon exercise of the Warrants. Assuming full exercise of the Warrants, the shares offered hereunder would represent approximately 36% of our outstanding common stock following such exercise. In addition, we may sell additional shares of common stoc

View Full Filing

View this S-1 filing on SEC EDGAR